Linking the activity of bortezomib in multiple myeloma and autoimmune diseases

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F14%3A33150559" target="_blank" >RIV/61989592:15310/14:33150559 - isvavai.cz</a>
Result on the web
<a href="http://www.sciencedirect.com/science/article/pii/S1040842814000821" target="_blank" >http://www.sciencedirect.com/science/article/pii/S1040842814000821</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.critrevonc.2014.05.003" target="_blank" >10.1016/j.critrevonc.2014.05.003</a>

Result language
angličtina
Original language name
Linking the activity of bortezomib in multiple myeloma and autoimmune diseases
Original language description
Since their introduction to the clinic 10 years ago, proteasome inhibitors have become the cornerstone of anti-multiple myeloma therapy. Despite significant progress in understanding the consequences of proteasome inhibition, the unique activity of bortezomib is still unclear. Disappointing results from clinical trials with bortezomib in other malignancies raise the question of what makes multiple myeloma so sensitive to proteasome inhibition. Successful administration of bortezomib in various immunological disorders that exhibit high antibody production suggests that the balance between protein synthesis and degradation is a key determinant of sensitivity to proteasome inhibition because a high rate of protein production is a shared characteristic inplasma and myeloma cells. Initial or acquired resistance to bortezomib remains a major obstacle in the clinic as in vitro data from cell lines suggest a key role for the beta 5 subunit mutation in resistance; however the mutation was not
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FR - Pharmacology and apothecary chemistry
OECD FORD branch
—

Project
<a href="/en/project/EE.2.3.20.0062" target="_blank" >EE.2.3.20.0062: An inexpensive drug Antabuse as anticancer remedy: mechanism of action and clinical trials</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)